Haydale Graphene Industries — Update 4 November 2015

Haydale Graphene Industries — Update 4 November 2015

Haydale Graphene Industries

Analyst avatar placeholder

Written by

Haydale Graphene Industries

Strengthening the offer

Advanced materials

QuickView

3 November 2015

Price

177p

Market cap

£20m

Share price graph

Share details

Code

HAYD

Listing

AIM

Shares in issue

11.45m

Business description

Haydale is focused on the commercialisation of graphene and other nanoparticle products using its proprietary plasma process, which functionalises the materials. The functionalisation enables nanomaterials to more effectively interact with host materials by introducing customised covalent bonds.

Bull

Plasma-based functionalising process still appears unique, with patents awarded in China and Europe.

Placing and open offer oversubscribed.

Commercial development agreements in place with major resin suppliers.

Bear

Graphene remains a nascent material surrounded by a lot of hopeful rhetoric.

Haydale remains loss-making despite addition of profitable HCS; cash break-even expected FY17.

Very fragmented market means competition could emerge unexpectedly, from any region.

Analysts

Andy Chambers

+44 (0)20 3681 2525

Roger Johnston

+44 (0)20 3077 5722

Haydale has announced a successful placing and launched an open offer to raise £5.6m net through the issue of 3.75m shares at 160p. Combined with a number of positive developments since the IPO in April 2014, and following solid FY15 results, the company appears well-positioned to continue its progress. Focus on graphene-enhanced inks and composites end-markets appears to us to bring closer commercial success.

Fund-raising and FY15 results

Management states that the main placing of 2.9m shares was oversubscribed. Its success marks the rehabilitation of Haydale following the IPO in April 2014. £2.6m of the proceeds will support its working capital requirements. Monies will also be used to invest in increased reactor capacity, which has expanded 15x in the last 18 months, and support development of processing centres of excellence in Korea, Germany and the US. Haydale reported results to 30 June 2015, which include Haydale Composite Solutions (HCS, formerly EPL) bought in November 2014. Excluding HCS, sales more than doubled to £0.3m from £0.13. HCS outperformed expectations, although group adjusted EBITDA loss widened to £2.38m from £1.96m. Haydale had net cash of £2.05m at the year end.

Fast track to commercialised products

Haydale has secured a key European patent for its plasma-based functionalisation process, which enables the use in end products of nanomaterials such as graphene and graphene-like materials. While development of high-quality single sheet graphene may be some way off, areas targeted by Haydale may be commercialised more readily. It focuses on graphene-enhanced inks and composite resins, although sensors and energy markets may follow. For example, in the last year it has signed agreements with two resin suppliers (one polyester, one epoxy) to develop composite materials using functionalised graphene, which could more than double the strength of the composite and open up high-value markets. The process can be applied by any producer of nanomaterials requiring functionalised enhancement of products. In our view, Haydale’s process is currently unique.

Valuation: Still nascent, but progressing

The development of the graphene-related commercial products should be the main driver of sales over the remainder of the decade and may commence in FY16. Revenues should grow rapidly this year, with a full contribution from HCS augmented by the addition of graphene-enhanced product development projects as well as higher grant funding, the start of licensing and nascent commercial sales.

Consensus estimates

Year
end

Revenue
(£m)

PBT
(£m)

EPS
(p)

DPS
(p)

P/E
(x)

Yield
(%)

06/14

0.13

(2.22)

(0.28)

0.0

N/A

N/A

06/15

1.48

(3.03)

(0.25)

0.0

N/A

N/A

06/16e

2.70

(2.01)

(0.15)

0.0

N/A

N/A

06/17e

4.30

(1.00)

(0.07)

0.0

N/A

N/A

Source: Bloomberg (one estimate)

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER
Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document.
A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") (c) FTSE [2015]. "FTSE(r)" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 9258 1161

Level 25, Aurora Place

88 Phillip St, Sydney

NSW 2000, Australia

Wellington +64 (0)48 948 555

Level 15, 171 Featherston St

Wellington 6011

New Zealand

RXi Pharmaceuticals — Update 3 November 2015

RXi Pharmaceuticals

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free